Daravita Disclosure Statement Case 114-Cv-01118-UNA
of 1
description
Case 114-Cv-01118-UNADaravita (Alkermes) Patent Infringement Case Against Actavis with respect to the Manufacturing of Generic ZohydroER.ZohydroER is licensed by Zogenix and has exclusivity until fall 2016 by the FDA.
Transcript of Daravita Disclosure Statement Case 114-Cv-01118-UNA
-
5/20/2018 Daravita Disclosure Statement Case 114-Cv-01118-UNA
1/2
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
DARAVITA LIMITED,
Plaintiff,
v.
ACTAVIS LABORATORIES FL, INC.,
ANDRX CORPORATION, ACTAVIS
PHARMA, INC., and ACTAVIS, INC.,
Defendants.
)
)
))
)
))
)
))
)
C.A. No. ______________
DARAVITA LIMITEDS RULE 7.1 DISCLOSURE STATEMENT
Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Plaintiff Daravita Limited
states that it is a subsidiary of Alkermes plc, a publicly held corporation. No company currently
owns more than 10% of the stock of Alkermes plc.
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
/s/ Maryellen NoreikaJack B. Blumenfeld (#1014)Maryellen Noreika (#3208)Jeremy A. Tigan (#5239)
1201 N. Market Street
P.O. Box 1347Wilmington, DE 19899-1347
(302) 658-9200
[email protected]@mnat.com
Attorneys for Daravita Limited
September 3, 20148498179
Case 1:14-cv-01118-UNA Document 4 Filed 09/03/14 Page 1 of 1 PageID #: 46
-
5/20/2018 Daravita Disclosure Statement Case 114-Cv-01118-UNA
2/2
